Overall rank by patents
#44,609
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
ARO Biotherapeutics Company
USPTO PatentsView assignee record - 5 granted patents across 5 technology areas, active 2023–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA).
5
Total patents granted
5
CPC technology areas
37.0
Avg claims per patent
-
5-year filing velocity
The verdict
ARO holds 5 US patents across 5 technology areas, rank #44,609 of 50,000 tracked assignees.
- #44,609
- of 50,000 US assignees by volume
- Top 15%
- by Innovation Score (49.1/100)
- 37.0
- avg claims per patent
Portfolio overview
ARO Biotherapeutics Company has been granted 5 US utility patents between 2023 and 2025, placing ARO Biotherapeutics Company at rank #44,609 across all assignees tracked by PlainPatent. This portfolio spans 5 distinct Cooperative Patent Classification (CPC) subclasses, averaging 37.0 claims per patent with primary concentration in C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA). As a US Corporation, ARO Biotherapeutics Company is one of the more focused assignees in the PatentsView dataset. By volume, ARO sits between Argus Vision International Limited (5 patents, rank #44,605) and Arstroma Co., Ltd. (5 patents, rank #44,613) - the closest US assignees by grant volume. The composite Innovation Score of 49.1/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2023 through 2025, with 5 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. ARO Biotherapeutics Company's 37.0 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 5 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark ARO Biotherapeutics Company against peers pursuing similar technology classes.
Who files at ARO's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Argus Vision Inte…
ARGUS VISION INTERNATIONAL LIMITED
5 patents
- Ariel Premium Sup…
ARIEL PREMIUM SUPPLY, INC.
5 patents
- ARKH
ARKH, Inc.
5 patents
- Arlinea Industries
ARLINEA INDUSTRIES CO.
5 patents
- Arobotech Systems
AROBOTECH SYSTEMS, INC.
5 patents
- Arris Global
ARRIS Global Ltd.
5 patents
- ARS Electronica L…
ARS ELECTRONICA LINZ GMBH & CO. KG
5 patents
- Arstroma
ARSTROMA CO., LTD.
5 patents
- ARO Biotherapeuti… ◀
ARO Biotherapeutics Company
5 patents
What this shows ARO holds 5 patents at rank #44,609, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near ARO
By rank, the assignees closest to #44,609 in granted patent volume.
- Argus Vision International Limited #44,605 · 5 patents
- Ariel Premium Supply, Inc. #44,606 · 5 patents
- ARKH, Inc. #44,607 · 5 patents
- Arlinea Industries Co. #44,608 · 5 patents
- Arobotech Systems, Inc. #44,610 · 5 patents
- Arris Global Ltd. #44,611 · 5 patents
- ARS Electronica LINZ Gmbh & Co. KG #44,612 · 5 patents
- Arstroma Co., Ltd. #44,613 · 5 patents
Leaders in C12N (Microorganisms OR Enzymes)
Other assignees with the most granted patents in ARO's primary technology class.
- Monsanto Technology Llc 1,335 in class
- The Regents Of The University Of California 1,161 in class
- Novozymes A/s 656 in class
- Immatics Biotechnologies Gmbh 647 in class
- Pioneer Hi-bred International, Inc. 623 in class
- President And Fellows Of Harvard College 594 in class
- Massachusetts Institute Of Technology 541 in class
- The Trustees Of The University Of Pennsylvania 537 in class
ARO's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
49 Top 15% higher than 85% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2023–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2023 | 2 | 40.0% |
| 2024 | 1 | 20.0% |
| 2025 | 2 | 40.0% |
Which technologies does ARO Biotherapeutics Company patent most?
Top 5 of 5 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Complex
Frequently Asked Questions
How many patents does ARO Biotherapeutics Company hold?
ARO Biotherapeutics Company holds 5 US granted patents filed between 2023 and 2025, spanning 5 technology areas.
What is ARO Biotherapeutics Company's Innovation Score?
ARO Biotherapeutics Company has an Innovation Score of 49.1 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does ARO Biotherapeutics Company focus on?
ARO Biotherapeutics Company's top technology area is C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA) with 5 patents. The company has filed patents in 5 CPC subclasses total.
Is ARO Biotherapeutics Company's patent filing rate increasing or decreasing?
Insufficient historical data is available to calculate a velocity trend for ARO Biotherapeutics Company.
What does claim depth mean for ARO Biotherapeutics Company's patents?
ARO Biotherapeutics Company's patents average 37.0 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the ARO Biotherapeutics Company patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
ARO's 5 grants land it in the top 15% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - ARO ranks #44,609 of 50,000. Top 50 holders
- Most of this portfolio concentrates in C12N - see who else leads that technology area. C12N leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.